UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 90

Sortiert nach

Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?

Frontiers in oncology, 2020-10, Vol.10, p.593383-593383

2020

Volltextzugriff (PDF)

The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers

Frontiers in immunology, 2023-08, Vol.14

2023

Volltextzugriff (PDF)

Mutant p53K120R expression enables a partial capacity to modulate metabolism

Frontiers in genetics, 2022-09, Vol.13

2022

Volltextzugriff (PDF)

Structure of p73 DNA-binding domain tetramer modulates p73 transactivation

Proceedings of the National Academy of Sciences - PNAS, 2012-04, Vol.109 (16), p.6066-6071

2012

Volltextzugriff (PDF)

P53 family members modulate the expression of PRODH, but not PRODH2, via intronic p53 response elements

PloS one, 2013-07, Vol.8 (7), p.e69152-e69152

2013

Volltextzugriff (PDF)

Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes

Molecular cancer research, 2011-03, Vol.9 (3), p.271-279

2011

Volltextzugriff (PDF)

Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia

Frontiers in oncology, 2021-08, Vol.11, p.684621-684621

2021

Volltextzugriff (PDF)

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab

Blood cancer journal (New York), 2020-09, Vol.10 (9), p.92, Article 92

2020

Volltextzugriff (PDF)

Potential Role of miRNAs in the Acquisition of Chemoresistance in Neuroblastoma

Journal of personalized medicine, 2021-02, Vol.11 (2), p.107

2021

Volltextzugriff (PDF)

TP53 Mutants in the Tower of Babel of Cancer Progression

Human mutation, 2014-06, Vol.35 (6), p.689-701

2014

Volltextzugriff (PDF)

Etoposide-resistance in a neuroblastoma model cell line is associated with 13q14.3 mono-allelic deletion and miRNA-15a/16-1 down-regulation

Scientific reports, 2018-09, Vol.8 (1), p.13762-15, Article 13762

2018

Volltextzugriff (PDF)

Mutant p53 K120R expression enables a partial capacity to modulate metabolism

Frontiers in genetics, 2022, Vol.13, p.974662

2022

Volltextzugriff (PDF)

Effect of N3-Methyladenine and an Isosteric Stable Analogue on DNA Polymerization

Journal of Nucleic Acids, 2010-01, Vol.2010, p.1-14

2010

Volltextzugriff (PDF)

Human transcription factors in yeast: the fruitful examples of P53 and NF-кB

FEMS yeast research, 2016-11, Vol.16 (7), p.fow083

2016

Volltextzugriff (PDF)

SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations

Biochimica et biophysica acta. General subjects, 2020-01, Vol.1864 (1), p.129440, Article 129440

2020

Volltextzugriff (PDF)

Influences of Base Excision Repair Defects on the Lethality and Mutagenicity Induced by Me-lex, a Sequence-selective N3-Adenine Methylating Agent

The Journal of biological chemistry, 2002-08, Vol.277 (32), p.28663-28668

2002

Volltextzugriff (PDF)

Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

American journal of hematology, 2021-05, Vol.96 (5), p.E168-E171

2021

Volltextzugriff (PDF)

Validation of the Alternative International Prognostic Score‐E (AIPS‐E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O‐CLL1‐GISL protocol

European journal of haematology, 2021-06, Vol.106 (6), p.831-835

2021

Volltextzugriff (PDF)

TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases

American journal of hematology, 2021-08, Vol.96 (8), p.E306-E310

2021

Volltextzugriff (PDF)

Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases

European journal of haematology, 2021-04, Vol.106 (4), p.493-499

2021

Volltextzugriff (PDF)

Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab‐bendamustine: Results of study on 486 cases outside clinical trials

American journal of hematology, 2021-08, Vol.96 (8), p.E269-E272

2021

Volltextzugriff (PDF)

Abstract 3402: ΔN-p63α and TA-p63α exhibit intrinsic differences in transactivation specificities that depend on distinct features of DNA target sites

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.3402-3402

2014

Volltextzugriff (PDF)

Relationship between DNA Methylation and Mutational Patterns Induced by a Sequence Selective Minor Groove Methylating Agent

The Journal of biological chemistry, 1999-06, Vol.274 (26), p.18327-18334

1999

Volltextzugriff (PDF)

Antitumor Effects of PRIMA-1 and PRIMA-1 Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?

Cells (Basel, Switzerland), 2021-01, Vol.10 (1)

2021

Volltextzugriff (PDF)

1 – 25 von 90

Suche als RSS-Feed

Aktive Filter

ThemaMutation

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(86)

Publikationsform

Artikel
(90)

Sprache

Englisch
(90)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(57)
Life Sciences & Biomedicine
(54)
Humans
(30)
Biological And Medical Sciences
(19)
Molecular Sequence Data
(17)
Base Sequence
(16)
Genetics & Heredity
(15)
Oncology
(15)
Biochemistry & Molecular Biology
(14)
Toxicology
(13)
Hematology
(12)
Medical Sciences
(12)
Adenine - Analogs & Derivatives
(11)
Female
(10)
Netropsin - Analogs & Derivatives
(10)
Tumor Suppressor Protein P53 - Genetics
(10)
Animals
(9)
Dna Mutational Analysis
(9)
Adenine - Metabolism
(8)
Male
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?

The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers

Mutant p53K120R expression enables a partial capacity to modulate metabolism

Structure of p73 DNA-binding domain tetramer modulates p73 transactivation

P53 family members modulate the expression of PRODH, but not PRODH2, via intronic p53 response elements

Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes

Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab

Potential Role of miRNAs in the Acquisition of Chemoresistance in Neuroblastoma

TP53 Mutants in the Tower of Babel of Cancer Progression

Etoposide-resistance in a neuroblastoma model cell line is associated with 13q14.3 mono-allelic deletion and miRNA-15a/16-1 down-regulation

Mutant p53 K120R expression enables a partial capacity to modulate metabolism

Effect of N3-Methyladenine and an Isosteric Stable Analogue on DNA Polymerization

Human transcription factors in yeast: the fruitful examples of P53 and NF-кB

The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia

SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations

Influences of Base Excision Repair Defects on the Lethality and Mutagenicity Induced by Me-lex, a Sequence-selective N3-Adenine Methylating Agent

Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

Validation of the Alternative International Prognostic Score‐E (AIPS‐E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O‐CLL1‐GISL protocol

TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases

Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases

Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab‐bendamustine: Results of study on 486 cases outside clinical trials

Abstract 3402: ΔN-p63α and TA-p63α exhibit intrinsic differences in transactivation specificities that depend on distinct features of DNA target sites

Relationship between DNA Methylation and Mutational Patterns Induced by a Sequence Selective Minor Groove Methylating Agent

Antitumor Effects of PRIMA-1 and PRIMA-1 Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?

Aktive Filter

Suchergebnisse filtern